Preoperative PET/CT  18 F-FDG Standardized Uptake by Lymph Nodes as a Significant Prognostic Factor in Patients with Colorectal Cancer

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Purpose

We evaluated the prognostic value of preoperative ¹⁸F-FDG uptake by suspected lymph nodes (LNs) using ¹⁸F-FDG PET/CT in colorectal cancer patients.

Methods

Patients with CRC underwent ¹⁸F-FDG PET/CT before radical surgery. We used Cox proportional hazards regression to examine the relationship between recurrence and the ¹⁸F-FDG maximum standardized uptake value (SUVmax) in the suspected LNs (SUV _LN) on ¹⁸F-FDG PET/CT.

Results

Clinical data, treatment modalities, and results from 90 CR C patients were reviewed. The median follow-up was 19 months (range 3 to 72 months). Receiver operating characteristic analysis identified SUV _LN 1.15 was the optimal cut-off value for predicting recurrence. SUV _LN correlated with tumour size ( P=0.045), lymph node metastasis ( P=0.03), and recurrence ( P < 0.0001). Univariate analysis showed significant associations between recurrence and SUV _LN ( P=0.017), and tumour grade ( P=0.013). Multivariate analysis identified SUV _LN ( P < 0.0001), and tumour grade ( P=0.005) as independent risk factors for recurrence. Patients with SUV _LN ≤ 1.15 and SUV _LN > 0.15 differed significantly in terms of recurrence ( P < 0.0001).

Conclusion

Preoperative SUV _LN measured by ¹⁸F-FDG PET/CT was significantly associated with recurrence and had significant prognostic value for recurrence-free survival in patients with colorectal cancer.

Related collections

Most cited references 20

Record: found
Abstract: found
Article: not found

Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study.

Dominique Elias, François Gilly, Florent Boutitie … (2010)

PURPOSE Peritoneal carcinomatosis (PC) from colorectal cancer traditionally is considered a terminal condition. Approaches that combine cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (PIC) have been developed recently. The purpose of this study was to assess early and long-term survival in patients treated with that strategy. PATIENTS AND METHODS A retrospective-cohort, multicentric study from French-speaking countries was performed. All consecutive patients with PC from colorectal cancer who were treated with CRS and PIC (with or without hyperthermia) were included. Patients with PC of appendiceal origin were excluded. Results The study included 523 patients from 23 centers in four French-speaking countries who underwent operation between 1990 and 2007. The median follow-up was 45 months. Mortality and grades 3 to 4 morbidity at 30 days were 3% and 31%, respectively. Overall median survival was 30.1 months. Five-year overall survival was 27%, and five-year disease-free survival was 10%. Complete CRS was performed in 84% of the patients, and median survival was 33 months. Positive independent prognostic factors identified in the multivariate analysis were complete CRS, PC that was limited in extent, no invaded lymph nodes, and the use of adjuvant chemotherapy. Neither the grade of disease nor the presence of liver metastases had a significant prognostic impact. CONCLUSION This combined treatment approach against PC achieved low postoperative morbidity and mortality, and it provided good long-term survival in patients with peritoneal scores lower than 20. These results should improve in the future, because the different teams involved will gain experience. This approach, when feasible, is now considered the gold standard in the French guidelines.

0 comments Cited 215 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Preoperative staging of non-small-cell lung cancer with positron-emission tomography.

H Groen, J V Houte, Randall J. Pruim … (2000)

Determining the stage of non-small-cell lung cancer often requires multiple preoperative tests and invasive procedures. Whole-body positron-emission tomography (PET) may simplify and improve the evaluation of patients with this tumor. We prospectively compared the ability of a standard approach to staging (computed tomography [CT], ultrasonography, bone scanning, and, when indicated, needle biopsies) and one involving PET to detect metastases in mediastinal lymph nodes and at distant sites in 102 patients with resectable non-small-cell lung cancer. The presence of mediastinal metastatic disease was confirmed histopathologically. Distant metastases that were detected by PET were further evaluated by standard imaging tests and biopsies. Patients were followed postoperatively for six months by standard methods to detect occult metastases. Logistic-regression analysis was used to evaluate the ability of PET and CT to identify malignant mediastinal lymph nodes. The sensitivity and specificity of PET for the detection of mediastinal metastases were 91 percent (95 percent confidence interval, 81 to 100 percent) and 86 percent (95 percent confidence interval, 78 to 94 percent), respectively. The corresponding values for CT were 75 percent (95 percent confidence interval, 60 to 90 percent) and 66 percent (95 percent confidence interval, 55 to 77 percent). When the results of PET and CT were adjusted for each other, only PET results were positively correlated with the histopathological findings in mediastinal lymph nodes (P<0.001). PET identified distant metastases that had not been found by standard methods in 11 of 102 patients. The sensitivity and specificity of PET for the detection of both mediastinal and distant metastatic disease were 95 percent (95 percent confidence interval, 88 to 100 percent) and 83 percent (95 percent confidence interval, 74 to 92 percent), respectively. The use of PET to identify the stage of the disease resulted in a different stage from the one determined by standard methods in 62 patients: the stage was lowered in 20 and raised in 42. PET improves the rate of detection of local and distant metastases in patients with non-small-cell lung cancer.

0 comments Cited 101 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Surveillance after curative treatment for colorectal cancer

Eric P. van der Stok, Manon C. W. Spaander, Dirk Grünhagen … (2016)

After curative treatment, 30% of patients with stage I–III and up to 65% of patients with stage IV colorectal cancer (CRC) develop recurrent disease. Thus, surveillance for disease recurrence is clearly needed in these patients, but controversy surrounds the optimal follow-up approaches. Herein, the current evidence relating to surveillance strategies for patients with CRC is comprehensively reviewed, and the future development of patient-centred programmes is discussed.

0 comments Cited 99 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Gang Huang:

ORCID: http://orcid.org/0000-0003-1939-3978

Jianjun Liu:

ORCID: http://orcid.org/0000-0003-3479-3849

Journal

Journal ID (nlm-ta): Contrast Media Mol Imaging

Journal ID (iso-abbrev): Contrast Media Mol Imaging

Journal ID (publisher-id): CMMI

Title: Contrast Media & Molecular Imaging

Publisher: Hindawi

ISSN (Print): 1555-4309

ISSN (Electronic): 1555-4317

Publication date Collection: 2018

Publication date (Electronic): 1 November 2018

Volume: 2018

Electronic Location Identifier: 5802109

Affiliations

¹Department of Nuclear Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

²Shanghai Key Laboratory for Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China

Author notes

Academic Editor: Gaurav Malviya

Author information

Gang Huang http://orcid.org/0000-0003-1939-3978

Jianjun Liu http://orcid.org/0000-0003-3479-3849

Article

DOI: 10.1155/2018/5802109

PMC ID: 6236575

SO-VID: 3e759f96-8f5e-400c-baba-ca57d3e2db65

License:

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

History

Date received : 25 June 2018

Date revision received : 27 August 2018

Date accepted : 30 September 2018

Funding

Funded by: National Natural Science Foundation of China

Award ID: 30830038

Award ID: 30970842

Award ID: 81071180

Award ID: 81471687

Award ID: 81572719

Award ID: 81571710

Award ID: 81601520

Award ID: 81601536

Award ID: 81701724

Award ID: 81701725

Award ID: 81771858

Award ID: 81830052

Award ID: 81530053

Funded by: Major State Basic Research Development Program of China

Award ID: 2012CB932604

Funded by: New Drug Discovery Project

Award ID: 2012ZX09506-001-005

Comments

Comment on this article

scite_

Cited by 9

See all cited by

Most referenced authors 577

See all reference authors

- Version 1